ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Autologous Anti-BCMA-CAR-mRNA-transfected CD8+ T-lymphocytes

Also written as “Descartes-08” and “Descartes 08”.

Its studies are mostly in Multiple Myeloma · Myositis · Myasthenia Gravis · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis · Lupus Erythematosus, Systemic, led by Cartesian Therapeutics.

Drug pageAutologous Anti-BCMA-CAR-mRNA-transfected CD8+ T-lymphocytes: every studyAll 6 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 2, since Oct 29, 20196 company-led studies, 4 open or runningNext primary completion: Dec 1, 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Cartesian Therapeutics64 open or runningphase 2since Oct 29, 2019Jan 24, 2018Dec 1, 2026phase 2 · NCT06038474

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 24, 2018First study: phase 1 study in Multiple MyelomaFirst studyNCT03448978 · 32 enrolled · United States
  2. Oct 29, 2019Phase 2 study in Myasthenia GravisNCT04146051 · 30 enrolled · United States, Canada
  3. Mar 23, 2021Phase 2 study in Multiple MyelomaNCT04816526 · 13 enrolled · United States
  4. Sep 8, 2023Phase 2 study in Lupus Erythematosus, SystemicNCT06038474 · 6 enrolled · United States
  5. Jul 20, 2025Phase 2 study in Anti-Neutrophil Cytoplasmic Antibody-Associated VasculitisNCT07089121 · 50 planned · United States
  6. Jan 29, 2026Phase 2 study in Antisynthetase syndromeNCT07391605 · 60 planned · United States

Ahead

  1. Dec 1, 2026Primary completion: phase 2 study in Lupus Erythematosus, SystemicNCT06038474
  2. Nov 2027Primary completion: phase 2 study in Antisynthetase syndromeNCT07391605
  3. Dec 2027Primary completion: phase 2 study in Anti-Neutrophil Cytoplasmic Antibody-Associated VasculitisNCT07089121

TargetBeta

TNFRSF17 →read by rule
“A preparation of autologous CD8-positive T-lymphocytes that have been genetically modified via transient mRNA transfection to express a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) human B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily me”NCIt, by rule

Other programs on TNFRSF17

ProgramCompanyFurthest phaseStudies
elranatamabrulePfizerphase 415
linvoseltamabruleRegeneron Pharmaceuticalsphase 413
teclistamabruleJohnson & Johnsonphase 411
belantamab mafodotinruleGlaxoSmithKlinephase 325
Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012FAstraZenecaphase 312
etentamigAbbViephase 311
ramantamigJohnson & Johnsonphase 38
anitocabtagene autoleucelruleGilead Sciencesphase 36
equecabtagene autoleucelrulenanjing-iaso-biotechnology-co-ltdphase 35
Anti-CD3/Anti-BCMA Bispecific Antibody TQB2934Sino Biopharmaceuticalphase 34
GPRC5D/BCMA/CD3-targeting T-cell Engager IBI3003ruleInnovent Biologicsphase 34
Evarucabgene Autoleucelrulenexcella-incphase 32

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07391605Antisynthetase syndrome · United States2RecruitingNov 202760
NCT07089121Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis · United States2RecruitingDec 202750
NCT06038474Lupus Erythematosus, Systemic · United States2Active, not recruitingDec 1, 20266
NCT04816526Multiple Myeloma · United States2TerminatedAug 4, 202213
NCT04146051Myasthenia Gravis · United States, Canada2Active, not recruitingJan 5, 202630
NCT03448978Multiple Myeloma · United States1TerminatedApr 19, 202132

How it is read

Names in the registry

  • “Descartes-08”, 5 entries
  • “Descartes 08”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
Autologous Anti-BCMA-CAR-mRNA-transfected CD8+ T-lymphocytes (Cartesian Therapeutics): development program | ClinicalTrials.gg